Table 2.
Characteristics of all included studies.
| First author | Sample size (T/C) | Age (years) | Interventions | Duration treatment (weeks) | Outcomes | ||
|---|---|---|---|---|---|---|---|
| T | C | T | C | ||||
| Li 2019 | 60 (30/30) | 26-72 | 20-74 | QP | Sham ointment | 2 | ①②③④ |
| Tang 2011 | 228 (154/74) | 18-70 | 18-70 | QP | Sham ointment | 3 | ①②④ |
| Wang 2018 | 120 (60/60) | 2-11 | 2-12 | QP | Vaseline ointment | 2 | ①②④ |
| Zhang 2017 | 67 (34/33) | 2-12 | 3-12 | QP | Vaseline ointment | 2 | ①④ |
| She 2016 | 65 (33/32) | 2-12 | 2-12 | QP | Vaseline ointment | 2 | ①②④ |
| Zeng∗ 2013 | 69 (38/31) | 20-63 | 20-63 | QP | Vaseline ointment | 4 | ①②④ |
| Chen 2010 | 83 (43/40) | 29-68 | 31-69 | QP | Vaseline ointment | 4 | ①④ |
| Tang 2017 | 112 (56/56) | 22-64 | 21-63 | QP | Triamcinolone acetonide cream | 2 | ④ |
| Song 2017 | 87 (44/43) | 4-12 | 4-12 | QP | Hydrocortisone butyrate ointment | 4 | ③④ |
| Zhang 2016 | 64 (33/31) | 18-60 | 18-60 | QP | Hydrocortisone butyrate ointment | 4 | ①④ |
| Yang 2016 | 215 (108/107) | 18-64 | 17-58 | QP | Hydrocortisone butyrate ointment | 2 | ①②④ |
| Guo 2015 | 78 (38/40) | 15-70 | 16-68 | QP | Halometasone cream | 4 | ①④ |
| Huang 2014 | 77 (38/39) | 18-65 | 18-65 | QP | Hydrocortisone butyrate ointment | 3 | ①④ |
| Hou 2014 | 71 (34/37) | 18-72 | 18-72 | QP | Hydrocortisone butyrate ointment | 3 | ①④ |
| Zeng∗ 2013 | 73 (38/35) | 20-63 | 20-63 | QP | Mometasone furoate cream | 4 | ①②④ |
| Li∗ 2012 | 61 (29/32) | 18-69 | 18-75 | QP | Fluticasone propionate cream | 4 | ①④ |
| Zheng∗ 2012 | 80 (39/41) | 25-70 | 21-65 | QP | Mometasone furoate cream | 3 | ①②③ |
| Zhao 2011 | 65 (33/32) | 15-86 | 15-86 | QP | Hydrocortisone cream | 4 | ①②④ |
| Wang 2011 | 244 (126/118) | 18-65 | 16-60 | QP | Hydrocortisone butyrate ointment | 2 | ①②④ |
| Zeng 2011 | 44 (22/20) | 18-75 | 18-75 | QP | Hydrocortisone butyrate ointment | 4 | ④ |
| Yang 2018 | 74 (37/37) | 4-10 | 4-9 | QP + desonide ointment | Desonide ointment | 4 | ②③④ |
| Jiang 2017 | 100 (50/50) | 19-78 | 20-81 | QP + mometasone furoate cream | Mometasone furoate cream | 2 | ①③④ |
| Wang 2015 | 97 (54/43) | 35.69 | 34.54 | QP + hydrocortisone butyrate ointment | Hydrocortisone butyrate ointment | 2 | ② |
| Liu 2014 | 82 (40/42) | 21-70 | 19-72 | QP + halometasone cream | Halometasone cream | 2 | ① |
| Li∗ 2012 | 62 (30/32) | 21-72 | 18-75 | QP + fluticasone propionate cream | Fluticasone propionate cream | 2 | ① |
| Zheng∗ 2012 | 85 (44/41) | 18-72 | 21-65 | QP + mometasone furoate cream | Mometasone furoate cream | 1 | ①②③ |
| Zhou 2011 | 126 (63/63) | 15-70 | 15-70 | QP + halometasone cream | Halometasone cream | 2 | ①②④ |
| Zhai 2011 | 64 (32/32) | 16-64 | 16-64 | QP + fluticasone propionate cream | Fluticasone propionate cream | 2 | ①②④ |
| Peng 2011 | 85 (44/41) | 19-63 | 18-64 | QP + triamcinolone acetonide cream | Triamcinolone acetonide cream | 4 | ①②④ |
T: test group; C: control group; QP: Qingpeng ointment; ①: total efficacy rate; ②: total symptom score; ③: visual analogue scale for pruritus; ④: adverse events. ∗A three-arm study.